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Abstract 38 
This paper introduces and discusses key issues in the economic evaluation of digital health 39 
interventions.  The purpose is to stimulate debate so that existing economic techniques may 40 
be refined or new methods developed.  The paper does not seek to provide definitive 41 
guidance on appropriate methods of economic analysis for digital health interventions. 42 
 43 
We describe existing guides and analytical frameworks that have been suggested for the 44 
economic evaluation of health care interventions. Using selected examples of digital health 45 
interventions, we assess how well existing guides and frameworks align to digital health 46 
interventions.  We show that digital health interventions may be best characterised as 47 
complex interventions in complex systems.  Key features of complexity relate to intervention 48 
complexity, outcome complexity and causal pathway complexity, with much of this driven by 49 
iterative intervention development over time and uncertainty regarding likely reach of the 50 
interventions amongst the relevant population.  These characteristics imply that more 51 
complex methods of economic evaluation are likely to be better able to capture fully the 52 
impact of the intervention on costs and benefits over the appropriate time horizon.  This 53 
complexity includes wider measurement of costs and benefits, and a modelling framework 54 
that is able to capture dynamic interactions between the intervention, the population of 55 
interest and the environment.  We recommend that future research should develop and apply 56 
more flexible modelling techniques, to allow better prediction of the inter-dependency 57 
between interventions and important environmental influences.    58 
 59 
 60 
 61 
 62 
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 65 
Background 66 
The purpose of economic evaluations of digital health interventions (DHIs) is to inform 67 
decision-makers about the relative value for money of those interventions against specified 68 
alternatives.  With resource scarcity, it is argued that use of resources will be more efficient if 69 
these are allocated to interventions where the magnitude of additional benefits relative to the 70 
magnitude of additional costs is greatest, subject to an identified budget constraint. 71 
 72 
There are several ways to conduct an economic evaluation of health interventions. One of the 73 
most common is Cost-Utility analysis.  This measures benefits in terms of Quality Adjusted 74 
Life Years (QALYs), which is a measure of length of life weighted by quality of life to 75 
reflect desirability of that life (scaled from 0 to 1, where 0=dead and 1=perfect health). Other 76 
analyses include Cost-Effectiveness Analysis, which measures benefits in terms of clinical 77 
units, such as whether an individual is free of symptoms, and Cost-Consequences Analysis, 78 
an extended form of Cost-Effectiveness Analysis, where multiple benefits are measured and 79 
reported separately.  Within other public policy fields, such as environment and transport 80 
appraisal, the technique of Cost-Benefit Analysis is the most common type of evaluation, 81 
with the benefits of programs being measured in monetary terms. 82 
 83 
Several sets of guidelines for the design and conduct of economic evaluation exist for studies 84 
in health care,
1
 but the extent to which these are relevant to DHIs has received little attention.  85 
The term ‘digital health interventions’ in this paper refers to interventions that employ digital 86 
technology to promote and maintain health, through supporting behaviour change or decision 87 
making of the general public, patients or healthcare practitioners.  Interventions are typically 88 
automated, interactive and personalized, employing user input or sensor data to tailor 89 
6 
 
 
feedback or treatment pathways (e.g. a smartphone app to promote greater levels of physical 90 
activity would be one example).  In telemedicine and telecare, which may be component parts 91 
of some DHIs, systematic reviews suggest there is a lack of good evidence regarding costs 92 
and therefore cost-effectiveness,
2,3
 and this partly arises through lack of methodological 93 
rigour within the original published studies.
4
     94 
 95 
The paper does not seek to provide definitive guidance on appropriate methods of economic 96 
analysis for DHIs, but instead aims to highlight key issues in the economic evaluation of 97 
DHIs, in order to stimulate debate so that refined economic tools and methods may in due 98 
course be developed. The paper is organised along the following lines.  First, we describe 99 
existing guides and analytical frameworks suggested for the economic evaluation of 100 
interventions applied to complex interventions.  Second, using selected examples of DHIs, 101 
we assess how well existing guides and frameworks map to DHIs.  Third, we propose key 102 
decision points in the design and conduct of economic evaluations.   103 
  104 
7 
 
 
 105 
Existing Analytical Frameworks 106 
 107 
1. ISPOR Good Research Practice Guide 108 
To enhance the conduct and reporting of trial-based economic evaluation studies applied to 109 
new medicines, medical devices and procedures, the International Society for 110 
Pharmacoeconomics and Outcomes Research (ISPOR) has published an updated good 111 
research practice guide.
1
  This re-emphasises the need to base economic evidence on 112 
effectiveness rather than efficacy, the benefits from direct data collection on resource use and 113 
health states (or other measures of effectiveness) from study participants rather than 114 
indirectly (such as mapping), and recognising that study designs such as randomised 115 
controlled trials (RCTs) are complementary to model-based evaluations.  These 116 
recommendations appear salient for evaluation of DHIs.  For example, there is already 117 
recognition that RCTs are not always appropriate as a means to establish effectiveness,
 5
 and 118 
a similar argument holds for evaluation of cost-effectiveness.   119 
 120 
In some specific areas however, the recommendations may be less appropriate for DHIs.  For 121 
example, where interventions are designed in order to bring about health behaviour change, it 122 
can be argued that they differ from medicines, devices and procedures in terms of intended 123 
mechanisms of action.  Here notions of mechanism of action confined to biological 124 
interactions within single individuals have been significantly developed and refined,
6-9
 to 125 
accommodate importance of interaction with the health and social care system, or the wider 126 
social environment.     127 
 128 
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One area in particular where there may be a need for a different approach relates to the use of 129 
intermediate (surrogate) measures of benefit.  The ISPOR guide recommends that the use of 130 
“intermediate (or surrogate)” measures should be avoided in the measurement of benefit 131 
wherever possible.  However, when the expected effects of an intervention are only likely to 132 
be observed in the long-term, the guide suggests that surrogate measures are appropriate, as 133 
long as the relationship to “final” measures (e.g. mortality, health related quality of life, or 134 
well-being) is firmly established.  A focus on surrogate measures may not be sufficient in 135 
circumstances where intervention adapt and change over time, where the mechanisms of 136 
action are unclear and where effectiveness and cost-effectiveness is theorised to relate closely 137 
to the system or environment in which it is placed.  In short, existing guidelines such as the 138 
ISPOR guide, which are available for medicines, devices and procedures, may require 139 
amendment for many DHIs. 140 
 141 
2. MRC Framework for Complex Interventions 142 
 143 
DHIs can be characterised as ‘complex interventions’ in a complex system.10-12   Within the 144 
MRC Framework for the Evaluation of Complex Interventions,
13
 a complex intervention is 145 
one that “contains several interacting components, and other characteristics, such as the 146 
number and difficulty of behaviours required by those delivering or receiving the 147 
intervention”.  Complexity may also refer to features of the system in which an intervention 148 
is implemented, as well as the intervention itself.  Shiell et al
12
 note that “a complex system is 149 
one that is adaptive to changes in its local environment, is composed of other complex 150 
systems, and behaves in a non-linear fashion (i.e. change in outcome is not proportional to 151 
change in input)”.  Petticrew et al14 outline this further by drawing distinctions between 152 
intervention complexity, outcome complexity and causal pathway complexity: 153 
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 154 
 Intervention complexity: 155 
o Multiple, interacting components 156 
o Likely to be tailored, adapt or change over time 157 
 Outcome complexity: 158 
o Spillovers and externalities, i.e. outcomes go beyond the immediate recipient 159 
of the intervention, such as influencing the behaviour or health of other family 160 
members 161 
o Feedback loops, i.e. the uptake of the intervention may be affected by uptake 162 
by others, “social contagion” effect 163 
 Causal pathway complexity: 164 
o Multiple moderators and mediators of the relationship between intervention 165 
and outcomes, in particular strong influence of system characteristics (i.e. the 166 
setting/context of the intervention is important and likely to generate 167 
heterogeneity in costs and benefits, through differences in resource 168 
availability, culture, beliefs, attitudes, interpersonal relationships) 169 
o Non-linear relationships between intervention resource inputs and multiple 170 
outputs, “phase” changes, i.e. sudden, unpredictable tipping points 171 
 172 
A key question is the extent to which DHIs map to the above types of complexity.  Clearly 173 
some may align with the above classification more than others; for example, consider a health 174 
app for the management of type 2 diabetes - if additional input from health care staff is 175 
required according to individual patient goals or preferences, or if the intervention partly 176 
comprises an element of feedback from health care staff, then this gives rise to intervention 177 
complexity – the intervention is highly individualised and heterogeneous.   There may also be 178 
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outcome complexity, e.g. if the individual needs to change food and alcohol intake, then other 179 
household members may also have to change, but may be resistant to this.  Further, if the app 180 
includes the option of information exchange with other users, e.g. electronic posting of goals 181 
achieved, this could affect behaviour in a positive or negative way.  Finally, there may need 182 
to be a set of necessary conditions in place for the intervention to be effective, especially in 183 
the longer-term; these could relate to a set of motivational factors, such as prior diabetes 184 
history, other patient characteristics (education, income, and time preference in terms of 185 
willingness to invest time and effort today in order to achieve additional benefits later) and 186 
wider contextual factors, such as an individual being within a social network where members  187 
already undertake “healthy behaviours”.  These conditions give rise to causal pathway 188 
complexity. Taken together, it could be argued that the health app intervention is a complex 189 
intervention in a complex system.  Conversely, other DHIs for the same condition may 190 
exhibit less complexity, for example, if there is little or no interaction with health care 191 
professionals or other recipients, then causal pathway complexity is likely to be smaller. 192 
 193 
Taking forward these notions, Shiell et al
12
 draw out some lessons for economic evaluation; it 194 
is argued that, where a complex intervention lacks significant interaction with the setting, i.e. 195 
where the casual pathway is relatively simple, current methods of economic evaluation might 196 
be sufficient, i.e. identifying, measuring and valuing resource use and weighing that against 197 
the value of health or other outcomes that are produced.   However, where there is significant 198 
interaction with setting, there are potentially additional challenges for economic evaluation.  199 
These include more difficult choices regarding what measures of effectiveness should be 200 
included, how consequences should be valued, and how evaluation should be conducted.  201 
More fundamentally, there may be significant challenges associated with historicity or path 202 
dependence. For instance, the past twenty years have seen a marked change in public 203 
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acceptability of smoking and use of mobile devices, so it may be hypothesised that a DHI 204 
intervention to encourage smoking cessation may have achieved very different effects at any 205 
point during that period.  These challenges may lead therefore to a need to conduct a 206 
“complex economic evaluation”, e.g. attempting to estimate cost-effectiveness for sub-groups 207 
according to the extent of interaction with the system or with each other.  (Note however that 208 
it is still legitimate to conduct “simple” evaluations of complex interventions, by addressing 209 
“simple” questions,14 e.g. what is the average change in health and costs after intervention 210 
receipt, relative to usual care?).  Ultimately, the type of evaluation conducted will depend on 211 
the research question, as well as extent of interaction, between intervention and 212 
system/setting, or between individuals, and the importance this has for generating 213 
heterogeneity in costs and benefits.   214 
 215 
To illustrate what a complex economic evaluation might look like, consider Zhang et al,
15
  216 
who used an agent-based model of social network interactions to examine the effect of 217 
different policy instruments in changing dietary behaviours (Figure 1).  Based on a multi-218 
level theory of population health that encompasses habitual behaviours,
16
 behaviours are 219 
influenced by standard economic incentives, such as price, but also affected by cognitive 220 
habits that are subject to social norms.  The model simulated potential policy impacts (e.g 221 
taxation), and could be extended by incorporating data from natural experiments and health 222 
administrative records, to examine influences on health, well-being and costs to the health 223 
care system.  224 
 225 
Whether simple or complex, a key factor in economic evaluation relates to judgement 226 
regarding the time frame for the expected effects to occur.  This creates a challenge for DHIs 227 
as the content of many interventions evolves over time, and there may be a protracted period 228 
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before benefits are observed.  Conventional approaches have usually been built on the 229 
randomised controlled trial (RCT).  The RCT is designed to determine whether the 230 
relationship between a constant (the independent variable) and the outcome of the interaction 231 
it has with the environment into which it is applied is free from bias.  So long as the 232 
intervention is constant, then this is appropriate.  But some DHIs are not constant, with many 233 
evolving as they are implemented. As a result, the artificial nature of RCTs may mean that 234 
they are not good vehicles to indicate the potential impact of DHIs.   235 
 236 
If trials with randomisation at the individual level are potentially problematic, what are the 237 
alternative options?  Aside from cluster-randomisation, other study designs such as natural 238 
experiments are possible.
17
   For example, the five test bed sites within NHS England  239 
provide a vehicle to examine effectiveness and cost-effectiveness on a large scale.
18
  240 
However, use of quasi-experimental or observational study designs to demonstrate 241 
effectiveness also carries limitations, such as inability to control for unobserved variables.
17
  242 
More fundamentally, in many cases an evaluation will be needed by decision-makers before 243 
the DHI has been trialled, and in cases where a trial does proceed, by the time it is nearing 244 
completion, both its effectiveness and cost effectiveness will already be ‘known’ with 245 
sufficient accuracy before real-world data are available.  This may then provide disincentives 246 
for the future use of real-world data to examine effectiveness and cost-effectiveness. This 247 
suggests that a decision-theoretic approach will be required (and may be sufficient by itself) 248 
in some circumstances, such as where the intervention could not conceivably cause harm, and 249 
where the likely effect size would produce an estimate of cost-effectiveness that is well below 250 
currently acceptable thresholds.
19,20
 For example, the PRIMIT handwashing intervention was 251 
designed for use in a flu pandemic;
21
  here, international dissemination of a fully automated 252 
digital intervention to reduce spread of respiratory infection would likely result in healthcare 253 
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savings and wider health and socio-economic benefits so great that the cost of the 254 
intervention becomes negligible. 255 
 256 
Within the framework of complex interventions in complex systems, a critical factor driving 257 
effectiveness may be the extent of uptake by a social network or other relevant population. 258 
The argument here is that changes in health behaviour can be spread or transmitted from one 259 
individual to another within a social network; the parallel is earlier work on obesity and the 260 
idea that this is partly a social disease, through a clustering effect.
22
  In similar fashion, the 261 
effectiveness and cost-effectiveness of DHIs may depend on diffusion through social 262 
networks for uptake and effect.  For example, an internet-delivered hand washing 263 
intervention resulted in reductions in respiratory infection in the user and also in family 264 
members who had not engaged with the intervention directly,
21
 and smaller effects could 265 
spread more widely.  In addition, there may be feedback loops and potentially non-linear 266 
relationships, such as effectiveness at the individual level being partly dependent on nature of 267 
uptake at the group level (e.g. ‘The GCC challenge’ www.gettheworldmoving.com).23  268 
 269 
Since Christakis & Fowler
22,24,25
 there has been an explosion of epidemiological studies using 270 
social network analytical methods for describing and understanding network effects.
26
  271 
However, there have been far fewer published attempts to use such methods as the basis for 272 
the design and evaluation of DHIs.
27,28
  This may be because development of experimental 273 
methods in social networks analysis is still at a relatively early stage,
29,30
 and there is need to 274 
develop the wider use of modelling techniques for predicting social network effects.
31
  275 
 276 
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Implications of Applying the Complexity Framework for Economic Evaluation of 277 
Digital Health Interventions 278 
 279 
In situations where it is judged that applying standard methods of economic evaluation may 280 
not be optimal, there are implications for costs as well as for benefits, and also major 281 
challenges for selection of the appropriate modelling framework.  We turn to these issues 282 
below, by discussing implications in three areas: inclusion of development costs, 283 
measurement of benefits and resource use impacts, and the appropriate modelling 284 
framework.  285 
  286 
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 287 
1. Inclusion of development costs plus maintenance & running costs, or only the latter? 288 
 289 
The vast majority of costs are incurred during development.  Development costs may 290 
include: 291 
 Literature reviews, summarising available evidence on:  292 
o The condition addressed by the DHI (causes, treatments); 293 
o Interventions likely to be effective if delivered digitally (e.g. tailored 294 
content, behaviour change techniques, emotional support); 295 
 De novo research identifying user “wants and needs” 296 
 Costs of content development (this will vary with the intended goal of the 297 
DHI, but may include information provision, behaviour change interventions, 298 
decision support, emotional or psychological interventions, opportunities to 299 
interact online with peers or health care professionals) 300 
 Costs of design features (navigation, images, videos, graphics) 301 
 Costs of software features (interactivity, algorithms, tailoring) 302 
 Costs of user experience testing 303 
These costs can be substantial, ranging from £20,000 (for a simple one session intervention)
32
 304 
to £500,000 (or more) for a longitudinal, highly interactive intervention with extensive 305 
content, tailored to many different variables.
33
 Many of these costs relate to iterative 306 
development and evaluation of the intervention to maximise acceptability and feasibility.
34,35
   307 
In contrast, maintenance costs can be very low.  The minimum maintenance cost is hosting. 308 
Costs of hosting vary according to complexity of DHI and levels of security and response 309 
times required. 310 
16 
 
 
 311 
Although the issue of whether to include development costs, and other costs such as training 312 
costs and future costs of related diseases and treatments is not specific to DHIs, there are 313 
three additional considerations that may be peculiar to DHIs: 314 
 Most DHIs require regular updating to remain “the same”, e.g. where the DHI 315 
promises to deliver up-to-date information.  Updating is required for: a) content; b) 316 
navigation and visuals; and c) software.  As mainstream software manufacturers 317 
update their products, DHIs that are not updated will cease to function.  318 
 As outlined in Yardley et al,36 there is good evidence that DHIs alone are often not as 319 
effective as DHI + human support or facilitation, where the human input focuses on 320 
getting the patient (user) to use the DHI as intended.
37,38
  Unlike all other costs 321 
associated with DHIs, which are fixed, these facilitation costs are variable as they  322 
increase with each additional user.  323 
 Many interventions are likely to evolve unpredictably over time.  Such change makes 324 
reproducibility more challenging, and also data collection difficult if the change was 325 
quick and no measurement of resource use was planned.  Where change is planned as 326 
part of the intervention, this knowledge should be built into the cost estimates, 327 
otherwise there is a danger that the costs incurred in a research study may not be fully 328 
reflective of resource use outside of that setting.
35
 329 
 330 
The issue of perspective, i.e. whether the evaluation is conducted from a payer perspective, 331 
societal perspective or some other perspective, is also important in judging the importance of 332 
inclusion of development costs.  From the perspective of a national health regulator such as 333 
NICE, the decision may be whether to develop a DHI de novo and make it available as a 334 
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public good, i.e. once it is provided to at least one individual, it can be provided to an 335 
unlimited number of other people at no further cost.  Here, good estimates of fixed costs of 336 
development are important, alongside knowledge regarding resources required for storage, 337 
data retrieval, and encryption.  The payer (the NHS) would then agree a price with the 338 
manufacturer to cover these costs, together with a potential mark-up to protect intellectual 339 
property.  However, other perspectives than those of a national regulator can be adopted, and 340 
other factors, such as whether the DHI is a modification of an existing product, will have 341 
implications for the inclusion or exclusion development costs within the evaluation.  For 342 
example, for evaluation of existing products, prior development costs would usually be 343 
excluded, as these are “sunk costs” as there is no further resource impact for decision-makers 344 
going forward, but resources required for modification would be included.  Further, likely 345 
product reach and future costs of updating as technology changes are both highly 346 
unpredictable, and may be further affected by regulatory changes.   Information on reach is 347 
important in estimation of cost-effectiveness as the marginal costs per additional user will 348 
tend to zero as the population size.  This is not a trivial task, requiring additional effort and 349 
data analysis.
39
  350 
 351 
2. Measurement of benefits and resource use impacts 352 
The measurement of benefit should relate to the purpose of the individual technology – what 353 
is it trying to achieve over a particular time frame?  This is important because it acts as the 354 
key guide to how benefits are measured.  The main categories of benefit include the 355 
following: 356 
 health effects in their natural units, e.g. number of cancer cases avoided; 357 
 generic measures of healthy time and/or other outcomes, e.g. Quality Adjusted Life 358 
Years (QALYs); 359 
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 monetary valuation of healthy time and/or other outcomes, e.g. willingness to pay to 360 
gain  % increase in healthy life years; 361 
Less common approaches include measurement of changes in well-being, e.g. capability, the 362 
extent to which an individual feels it is possible for them to live a meaningful life,
40
 or 363 
measures of life satisfaction.
 364 
It is clear that different interventions are designed to achieve different objectives, some of 365 
which may relate to reductions in service use.  For example, DHIs for diabetes and for 366 
patients receiving warfarin
41
 are intended to reduce the need for monitoring visits with NHS 367 
staff.  Outcomes have been measured as change in utilisation of health care resources, patient 368 
satisfaction and maintained control of symptoms. For such DHIs it seems plausible to 369 
maintain an NHS perspective for costs and outcomes, i.e. only health effects, and health and 370 
social care costs may be deemed relevant for evaluation. (However, even here, it could be 371 
argued that a wider perspective is warranted, as patient monitoring of symptoms may increase 372 
reassurance and empowerment, but may also lead to adverse effects, such as anxiety and 373 
intrusiveness).  For other DHIs however, the range of benefits may be much wider and 374 
individual health effects may take longer to occur. These include internet based programs and 375 
apps to encourage a lifestyle change, such as weight loss, exercise or sleep behaviour, which 376 
may result in health changes as well as other effects, such as greater social inclusion and 377 
productivity changes. 378 
 379 
Finally, an important issue relates to safety.  There may be unintentional and intentional 380 
harms.  For example, a weight loss mobile app shared among teenage girls may give rise to 381 
unintended consequences such as an increase in smoking.   Digital apps also exist to help 382 
individuals to commit suicide. Some provide advice that is opposite to existing guidelines. 383 
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National regulation is therefore important.  Equally, regulation is appropriate to protect 384 
consumers from fraudulent apps, such as those purporting to measure Blood Alcohol 385 
Concentration, but with no capacity to do so.
42
  Further, harm may occur if information or 386 
advice in a DHI is inaccurate or out of date, or through misinterpretation by the user.  DHIs 387 
may also cause anxiety or feelings of inadequacy if users feel burdened by them.
43
   388 
  389 
3. Appropriate modelling framework 390 
Finally, there is the challenge of bringing costs and benefits together in the appropriate 391 
modelling framework.  In order to conduct evaluation that accounts for the degree of 392 
complexity that is relevant to the intervention and setting, it is vital that economic modellers 393 
develop or apply better tools to encapsulate individual and population level interactions, 394 
rather than impose highly simplified assumptions or heuristics about the nature of human 395 
behaviour.
44
  These models and the techniques to develop them should be more widely 396 
embraced in economic analysis of DHIs.
45
  As highlighted earlier,
15,16
 there appears a role for 397 
agent-based modelling.
46,47
  Within this approach, individuals make decisions autonomously, 398 
as well as interacting with others and with their environment using individually tailored 399 
“behavioural rules”.  These rules can be non-linear (e.g. discontinuous) and time-dependent 400 
(e.g. agents adapt and learn from previous experience).   401 
 402 
There is ample scope for methodological development in economic modelling in this field. A 403 
possible starting point may be a critical review of existing interventions and development of 404 
novel case studies.  For example, an ongoing EU collaboration, INTEGRATE-HTA, is 405 
examining aspects of complexity relevant to complex interventions in complex settings.
48
 406 
Many of these aspects are potentially relevant when considering DHIs; including the impact 407 
of multiple interacting agencies involved in the intervention and the wider system, problems 408 
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with defining the intervention due to characteristics like flexibility, tailoring, self-409 
organization, adaptivity and evolution over time, and issues of historicity or path dependence, 410 
whereby the evolution of the system through series of irreversible and unpredictable events 411 
means that generalizability and repeatability of an intervention is problematic. 412 
 413 
Concluding Comments - Key Decision Points in the Design & Conduct of Economic 414 
Evaluations for DHIs 415 
 416 
There is considerable scope for variation in how a particular DHI is delivered to a potential 417 
user, and the way in which that user then interacts with that intervention and the wider 418 
environment.  Moreover, feedback mechanisms may be critical to the success of that 419 
intervention, such that the wider environment has a strong effect on how a recipient uses a 420 
particular intervention. In short, many DHIs may be best characterised as complex 421 
interventions within a complex system, and within the class of complex interventions, they 422 
may hold special characteristics that require key questions to be addressed when planning  the 423 
design of an economic evaluation, outlined in Table 1: 424 
  425 
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 426 
Table 1.  Key guidance points and priority topics for future research 427 
Guidance points based on existing research 
 Assess whether an intervention is complex, e.g. does it involve adaptive intervention 
components or interaction with other people? Is the causal pathway from intervention 
to outcomes complex? i.e. are there multiple mediators or moderators of outcomes?  
 Consider whether a complex economic evaluation is appropriate. (e.g. can the 
research question be addressed using “standard” methods of economic evaluation 
which do not require modelling of patient-system-network relationships to generate 
robust cost and benefit estimates?) 
 For a given study perspective, identify the relevant and important costs that should be 
included in an economic evaluation. (e.g. should all the resources used in the 
development of the DHI be included? Alternatively, is it acceptable to focus solely on 
measurement of the health care resources and any other resources required in future 
maintenance and support of DHIs?) 
 For a given study perspective, identify the relevant and important benefits that should 
be included in an economic evaluation. (e.g. benefits are likely to be multi-faceted and 
potentially span beyond health, creating a challenge for measurement, e.g. does 
engagement with DHIs facilitate future employment prospects for some individuals? 
Are there other spin-offs?  Are there negative effects?  What effect does the DHI have 
on the wider environment, and what effect does the environment have on the DHI?) 
Priority topics for future research 
 Critical review of existing economic evaluations of digital health interventions, with 
particular focus on comparative studies that have undertaken different modelling 
approaches 
 Validation of agent-based models that capture dynamic interactions between the 
intervention, the population of interest and environment 
 Further interrogation of existing datasets to permit better estimates of reach and 
uptake of new digital health interventions 
 Exploration of how best to incorporate economic factors into intervention design and 
re-design  
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